Abstract:Triple negative breast cancer (TNBC) is a subtype of breast cancer (BC) that makes up 10–15% of BC diagnosis. This form of the disease disproportionately affects African American (AA) women as compared to women of other ethnicities. TNBC is classified by lack of expression of three receptors: Estrogen alpha (ERα), progesterone (PR) and human epidermal growth factor 2 (HER2). These receptors are used as therapeutic targets for BC that express them. As specific targets are not present, surgery, radiation and chemotherapy have been the mainstay of therapy for TNBC. Recently, newer drugs have become available based on specific genetic and epigenetic mutations like BRCA1, however more treatment options need to be produced to reduce the mortality rate in this disease. A novel compound, 2, 3‐dichloro‐5, 8‐dimethoxy‐1, 4‐naphthoquinone (Z285) belongs to the class of naphthoquinones that demonstrate activities as anticancer, antimalarial, and antibacterial compounds. These compounds have also been shown to cause an increase in reactive oxygen species (ROS) production as well as affect signaling pathways associated with epidermal growth factor receptor (EGFR). Moreover, it has been reported that treatment with tamoxifen can cause cell death. This is based on the accumulation of the drug and its active metabolites within cells that may cause an increase in the ROS production ultimately leading to cellular death, even in ERα negative cell lines. In the current study, three triple negative cell lines, HCC1806, MDA MB 231 and HS578T were used. These cells were treated with Z285 and 4‐hydroxy tamoxifen (4OH‐Tam) for 24 or 72hr with 1, 2, 4, 8, 16μM and 3, 6, 12, 24, 48μM respectively. Synergestic activity was demonstrated using SynergyFinder as well as the Chou‐Talalay method (CompuSyn). In other experiments, cells were treated with the IC50 of Z285 which was established in prior experiments. mRNA and protein were isolated between 6 and 24hr. Results showed alterations of several mRNA in response to these treatments. In addition, there were modifications to Nrf2 protein concentration, a transcription factor associated with oxidative stress. Therefore, these results indicate that combination treatment of Z285 and 4OH‐Tam induce cell death at lower concentrations. Thus this novel compound which causes an increase in ROS in these TNBC cells, may render them more susceptible to tamoxifen therapy. Charles and Mary Latham Fund

Anti-migration and anti-invasion effects of 2-hydroxy-6-tridecylbenzoic acid is associated with the enhancement of CYP1B1 expression through activating the AMPK signaling pathway in triple-negative breast cancer cells

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 Axis of Breast Cancer Cells: Combined Administration of Polydatin and 2‐Deoxy‐d‐glucose

Unveiling the therapeutic potential: KBU2046 halts triple-negative breast cancer cell migration by constricting TGF-β1 activation in vitro

Combination of Thiazolidinedione and Hydralazine Suppresses Proliferation and Induces Apoptosis by PPARγ Up-Expression in MDA-MB-231 Cells

Caffeic acid inhibits the tumorigenicity of triple-negative breast cancer cells through the FOXO1/FIS pathway

Synthesis and mechanism of action of new purine derivatives against triple negative breast cancer

Saikosaponin A Inhibits Triple-Negative Breast Cancer Growth and Metastasis Through Downregulation of CXCR4

Radix Tetrastigma Extracts Enhance the Chemosensitivity in Triple-Negative Breast Cancer Via Inhibiting PI3K/Akt/mTOR-Mediated Autophagy

Identifying the Effect of Ursolic Acid Against Triple-Negative Breast Cancer: Coupling Network Pharmacology With Experiments Verification

Proliferation, migration and invasion of triple negative breast cancer cells are suppressed by berbamine via the PI3K/Akt/MDM2/p53 and PI3K/Akt/mTOR signaling pathways

Naphthoquinone-derived ZSW-4B induces apoptosis in triple-negative breast cancer via AMPK signalling activation

Regulation of AMPK-related Glycolipid Metabolism Imbalances Redox Homeostasis and Inhibits Anchorage Independent Growth in Human Breast Cancer Cells

Phytoagent Deoxyelephantopin and Its Derivative Inhibit Triple Negative Breast Cancer Cell Activity through ROS-Mediated Exosomal Activity and Protein Functions

Targeted delivery of Saikosaponin A and doxorubicin via hyaluronic acid-modified ZIF-8 nanoparticles for TNBC treatment: Inhibiting metastasis and reducing cardiotoxicity

Hesperidin PLGA nanoparticles potentiate the efficacy of aPD-1 in treating triple negative breast cancer by regulating CCL2 and ADPN expression in cancer-associated adipocytes

The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer

Decreased Cell Proliferation with 2, 3‐ Dichloro‐5, 8‐Dimethoxy‐1, 4‐Naphthoquinone and 4‐Hydroxy Tamoxifen in Triple Negative Breast Cancer Cell Lines

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy

Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer

Genomic and GeneChip expression profiling reveals the inhibitory effects of Amorphophalli Rhizoma in TNBC cells

Coix Seed Oil Exerts an Anti–Triple-Negative Breast Cancer Effect by Disrupting miR-205/S1PR1 Axis